(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 9.8% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Neogenomics's revenue in 2026 is $727,332,000.On average, 15 Wall Street analysts forecast NEO's revenue for 2026 to be $104,452,097,459, with the lowest NEO revenue forecast at $101,022,458,844, and the highest NEO revenue forecast at $108,783,930,940. On average, 14 Wall Street analysts forecast NEO's revenue for 2027 to be $114,618,989,825, with the lowest NEO revenue forecast at $109,532,947,398, and the highest NEO revenue forecast at $120,627,997,072.
In 2028, NEO is forecast to generate $125,061,084,077 in revenue, with the lowest revenue forecast at $118,501,673,056 and the highest revenue forecast at $131,499,769,743.